ArticleBrain, behavior, & immunity - health2025
The effect of dual inflammation on the acute phase clinical outcomes of schizophrenia patients with comorbid COVID-19.
Article in Brain, behavior, & immunity - health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Concomitant pathologies and their impact on schizophrenia: a narrative overview of current evidence.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and hypothesis: Inflammation plays a crucial role in pathological mechanisms in schizophrenia (SZ) and the coronavirus disease 2019 (COVID-19), but the impact of dual inflammation on SZs' clinical outcomes is poorly understood. This study aimed to investigate whether dual inflammation impacts acute phase outcomes in patients with schizophrenia comorbid with COVID-19 (COVID-SZs). Study design: A total of 114 SZs and 49 COVID-SZs were recruited for this study. Plasma samples were collected and analyzed for levels of routine blood and inflammatory cytokines from all the participants. Then clinical symptoms, cognitive performance, and functional assessments were conducted at recruitment. One-way analysis of covariance examined the differences in inflammatory cytokines and correlation analyses examined the relationship between inflammatory cytokines and clinical outcomes. Study results: After controlling for age, gender, substance use status, and antipsychotic medications, levels of inflammatory cytokines increased in COVID-SZs groups compared to SZs groups. There were significantly higher total Positive and Negative Syndrome Scale (PANSS) scores and positive PANSS scores in COVID-SZs groups compared to SZs. As for cognitive performance, the COVID-SZs group had significantly worse performance in processing speed and attention than the SZs. The COVID-SZs group had significantly worse health status compared to the SZs. There were significantly different correlation patterns between the severity of psychiatric symptoms and inflammatory cytokines in COVID-SZs and SZs group. Conclusions: Findings indicate that dual inflammation exacerbates the acute phase clinical outcome of COVID-SZs. Suggesting a combined anti-inflammatory drug or the use of potentially anti-inflammatory antipsychotics in the acute phase of treatment to mitigate central nervous system damage. Regular monitoring of inflammatory marker levels can help reduce the risk of fluctuating psychiatric symptoms in patients with schizophrenia caused by inflammatory storms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.